284 related articles for article (PubMed ID: 34689339)
61. The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies.
Radawski CA; Hammad TA; Colilla S; Coplan P; Hornbuckle K; Freeman E; Smith MY; Sobel RE; Bahri P; Arias AE; Bennett D
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1532-1539. PubMed ID: 33146901
[TBL] [Abstract][Full Text] [Related]
62. European Medicines Agency Perspective on Oncology Study Design for Marketing Authorization and Beyond.
Jonsson B; Martinalbo J; Pignatti F
Clin Pharmacol Ther; 2017 May; 101(5):577-579. PubMed ID: 28073148
[TBL] [Abstract][Full Text] [Related]
63. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
Arondekar B; Duh MS; Bhak RH; DerSarkissian M; Huynh L; Wang K; Wojciehowski J; Wu M; Wornson B; Niyazov A; Demetri GD
Clin Cancer Res; 2022 Jan; 28(1):27-35. PubMed ID: 34667027
[TBL] [Abstract][Full Text] [Related]
64. Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?
Bujar M; Ferragu S; McAuslane N; Liberti L; Kühler TC
Clin Ther; 2021 May; 43(5):888-905. PubMed ID: 33883070
[TBL] [Abstract][Full Text] [Related]
65. Real-World Evidence to Inform Regulatory Decision Making: A Scoping Review.
Jansen MS; Dekkers OM; le Cessie S; Hooft L; Gardarsdottir H; de Boer A; Groenwold RHH
Clin Pharmacol Ther; 2024 Jun; 115(6):1269-1276. PubMed ID: 38390633
[TBL] [Abstract][Full Text] [Related]
66. Leveraging Real-World Evidence: A Paradigm Shift in Regulation.
De S; Larson L; Kelly K; Hanson B; Mack CD
J Orthop Trauma; 2021 Mar; 35(Suppl 1):S13-S16. PubMed ID: 33587541
[TBL] [Abstract][Full Text] [Related]
67. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Webster J; Smith BD
Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
[TBL] [Abstract][Full Text] [Related]
68. Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies.
Burns L; Kalesnik-Orszulak R; Spring R; Zeegers F; Rutstein M; Hukkelhoven M; Wruck L; O'Donnell J
Adv Ther; 2022 Oct; 39(10):4772-4778. PubMed ID: 35972721
[TBL] [Abstract][Full Text] [Related]
69. Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop.
Claire R; Elvidge J; Hanif S; Goovaerts H; Rijnbeek PR; Jónsson P; Facey K; Dawoud D
Front Pharmacol; 2023; 14():1289365. PubMed ID: 38283835
[No Abstract] [Full Text] [Related]
70. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
71. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
Sievers H; Joos A; Hiligsmann M
Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
[TBL] [Abstract][Full Text] [Related]
72. Assessing and Interpreting Real-World Evidence Studies: Introductory Points for New Reviewers.
Wang SV; Schneeweiss S
Clin Pharmacol Ther; 2022 Jan; 111(1):145-149. PubMed ID: 34416020
[TBL] [Abstract][Full Text] [Related]
73. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
74. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
Wallerstedt SM; Henriksson M
Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
[TBL] [Abstract][Full Text] [Related]
75. Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.
Breckenridge AM; Breckenridge RA; Peck CC
Br J Clin Pharmacol; 2019 Sep; 85(9):1874-1877. PubMed ID: 31290181
[TBL] [Abstract][Full Text] [Related]
76. Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World.
Burns L; Roux NL; Kalesnik-Orszulak R; Christian J; Hukkelhoven M; Rockhold F; O'Donnell J
Clin Ther; 2022 Mar; 44(3):420-437. PubMed ID: 35181179
[TBL] [Abstract][Full Text] [Related]
77. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA.
Dalla Torre Di Sanguinetto S; Heinonen E; Antonov J; Bolte C
Ther Innov Regul Sci; 2019 Jan; 53(1):86-94. PubMed ID: 29714594
[TBL] [Abstract][Full Text] [Related]
78. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
[TBL] [Abstract][Full Text] [Related]
79. Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World.
McNair D; Lumpkin M; Kern S; Hartman D
Clin Pharmacol Ther; 2022 Jan; 111(1):44-51. PubMed ID: 34655224
[TBL] [Abstract][Full Text] [Related]
80. [EMA approval procedures and assessment of innovation by AIFA: a cross sectional analysis.].
Lasala R
Recenti Prog Med; 2021 Apr; 112(4):273-284. PubMed ID: 33877088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
